source
- FDA advisory panel backs broader compounding of six peptide drugs despite limited safety dataAn FDA advisory panel reviewed seven peptide therapies and voted to ease access to six of them. The recommendation would let compounding pharmacies manufacture these peptides, expanding how they ca…
- RA Capital leads $175 million round for Oak Hill Bio to revive Roche’s Angelman syndrome drugRA Capital and other investors have committed $175 million to Oak Hill Bio, a new biotech aiming to revive a previously shelved experimental therapy for Angelman syndrome originally developed by Ro…